China Universal Asset Management Co., Ltd. Summit Therapeutics Inc. Transaction History

China Universal Asset Management Co., Ltd.

$773 Million
Q1 2024

A detailed history of China Universal Asset Management Co., Ltd. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 134,845 shares of SMMT stock, worth $929,082. This represents 0.07% of its overall portfolio holdings.

Number of Shares

134,845

Previous 134,845 -0.0%

Holding current value

$929,082

Previous $558,000 -0.0%

% of portfolio

0.07%

Previous 0.07%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$2.55 - $5.07 $137,123 - $272,634	53,774 Added 66.33%	134,845 $558,000
Q4 2023 May 21, 2024	SELL	$1.67 - $2.83 $89,802 - $152,180	-53,774 Reduced 39.88%	81,071 $211,000
Q4 2023 Jan 23, 2024	BUY	$1.67 - $2.83 $105,490 - $178,765	63,168 Added 352.83%	81,071 $212,000
Q3 2023 May 21, 2024	BUY	$1.54 - $2.42 $13,487 - $21,194	8,758 Added 95.77%	17,903 $33,000
Q3 2023 Oct 30, 2023	BUY	$1.54 - $2.42 $13,487 - $21,194	8,758 Added 95.77%	17,903 $33,000

Q2 2023 May 21, 2024	SELL	$1.32 - $2.81 $406 - $865	-308 Reduced 3.26%	9,145 $22,000
Q2 2023 Jul 27, 2023	SELL	$1.32 - $2.81 $406 - $865	-308 Reduced 3.26%	9,145 $23,000
Q1 2023 May 21, 2024	BUY	$1.38 - $5.41 $10,223 - $40,077	7,408 Added 362.25%	9,453 $16,000
Q1 2023 Apr 27, 2023	BUY	$1.38 - $5.41 $10,223 - $40,077	7,408 Added 362.25%	9,453 $17,000
Q4 2022 May 21, 2024	SELL	$0.68 - $5.31 $90,304 - $705,168	-132,800 Reduced 98.48%	2,045 $8,000
Q4 2022 Jan 31, 2023	BUY	$0.68 - $5.31 $108 - $849	160 Added 8.49%	2,045 $9,000
Q3 2022 Oct 21, 2022	BUY	$0.89 - $1.63 $1,677 - $3,072	1,885 New	1,885 $2,000

Others Institutions Holding SMMT

# of Institutions

107

Shares Held

41.3M

Call Options Held

103K

Put Options Held

29.9K

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $1.39B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account

China Universal Asset Management Co., Ltd. Summit Therapeutics Inc. Transaction History